The current study did not require STS expression for study entry but given that STS inhibition was not universal, that the only case to have an increase in Ki67 had a low STS expression and the targeted nature of irosustat it would seem appropriate to pre-select breast cancers for STS expression in any future studies. The gene discussed is MKI67; the disease is breast carcinoma.